On June 13, the U.S. Food and Drug Administration (FDA) announce new steps it is taking to address opioid addiction.
Opioid formulations with properties designed to deter abuse are not abuse-proof or addiction-proof. These drugs can still be abused, particularly orally, and their use can still lead . . .
Use of statins is associated with a higher risk for Parkinson’s disease, according to a study in Movement Disorders.
Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson’s disease (PD).
Statins may facilitate Parkinson’s disease: Insight . . .
Expanded use approval relies on real world evidence
The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death . . .
Children who participated in the PROSPER (PROmoting School-community-university Partnerships to Enhance Resilience) program over seven years ago showed lower rates of substance abuse after high school graduation, according to a new study conducted by researchers from Penn State and Iowa State Universities
PROSPER, a community-based preventive intervention . . .
On May 23, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for the treatment of unresectable or metastatic solid tumors with the biomarker microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Read more . . .
Low-dose intranasal oxytocin can influence how patients with autism perceive emotion, according to a study in Translational Psychiatry. Read more and access the study . . .
On April 27, the U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. It’s the first FDA-approved treatment for a liver cancer in almost a decade . . .
On April 28, the U.S. Food and Drug Administration (FDA) approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have the genetic mutation FLT3, in combination with chemotherapy. Read more . . .
On April 20, the U.S. Food and Drug Administration (FDA) announced that it is requiring a series of changes to labeling for codeine and tramadol to protect children and nursing mothers from harm. Read more . . .